55.45 (-%)
As of Nov 04, 2024
Source:
Bristol Myers Squibb Co is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. We expect that our acquisitions of MyoKardia in 2020 and Turning Point in 2022 will further position us as a leading biopharmaceutical company, expanding our precision oncology and cardiovascular portfolios with several near-term assets and additional external partnerships. Our principal strategy is to combine the resources, scale and capability of a pharmaceutical company with the speed and focus on innovation of the biotech industry.
Country | United States |
Headquarters | princeton, new jersey |
Phone Number | 6092524621 |
Industry | manufacturing |
CEO | Christopher Boerner, Ph.D. |
Website | www.bms.com |